(BKD) Brookdale Senior Living - Ratings and Ratios
Independent Living, Assisted Living, Memory Care, Skilled Nursing, CCRC
EPS (Earnings per Share)
Revenue
Dividends
Currently no dividends paid| Risk via 5d forecast | |
|---|---|
| Volatility | 45.4% |
| Value at Risk 5%th | 59.9% |
| Relative Tail Risk | -19.68% |
| Reward TTM | |
|---|---|
| Sharpe Ratio | 2.49 |
| Alpha | 142.41 |
| CAGR/Max DD | 1.51 |
| Character TTM | |
|---|---|
| Hurst Exponent | 0.483 |
| Beta | 0.870 |
| Beta Downside | 0.687 |
| Drawdowns 3y | |
|---|---|
| Max DD | 43.55% |
| Mean DD | 12.08% |
| Median DD | 9.60% |
Description: BKD Brookdale Senior Living January 16, 2026
Brookdale Senior Living Inc. (BKD) owns, manages, and operates a portfolio of senior-living communities across the United States, organized into three core segments: Independent Living (middle- to upper-income seniors in mixed independent/assisted units), Assisted Living & Memory Care (freestanding facilities providing 24-hour support and dementia-specific services), and Continuing Care Retirement Communities (CCRCs) that combine independent, assisted, memory-care, and skilled-nursing options, often under management-contract arrangements.
As of Q3 2024, Brookdale reported an overall occupancy of roughly 87% and an average daily rate (ADR) of about $3,500, reflecting strong demand from the aging Baby Boomer cohort. However, the company faces sector-wide pressures from rising labor costs, inflation-linked operating expenses, and tighter Medicare/Medicaid reimbursement rules-factors that compress margins unless offset by higher ADRs or cost-efficiency initiatives. The senior-housing market’s growth rate remains anchored to demographic trends, with the U.S. population aged 65+ projected to increase by 10% over the next five years, supporting long-term demand for both independent and higher-level care.
For a deeper dive into how Brookdale’s valuation stacks up against peers and the broader senior-care landscape, you might find ValueRay’s analytical tools useful.
Piotroski VR‑10 (Strict, 0-10) 3.0
| Net Income: -306.7m TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.01 > 0.02 and ΔFCF/TA 1.67 > 1.0 |
| NWC/Revenue: -3.23% < 20% (prev -3.73%; Δ 0.50% < -1%) |
| CFO/TA 0.04 > 3% & CFO 228.7m > Net Income -306.7m |
| Net Debt (5.24b) to EBITDA (441.3m): 11.88 < 3 |
| Current Ratio: 0.84 > 1.5 & < 3 |
| Outstanding Shares: last quarter (234.3m) vs 12m ago 2.72% < -2% |
| Gross Margin: 27.20% > 18% (prev 0.27%; Δ 2693 % > 0.5%) |
| Asset Turnover: 52.17% > 50% (prev 49.75%; Δ 2.42% > 0%) |
| Interest Coverage Ratio: 0.21 > 6 (EBITDA TTM 441.3m / Interest Expense TTM 306.0m) |
Altman Z'' -3.09
| A: -0.02 (Total Current Assets 536.9m - Total Current Liabilities 637.8m) / Total Assets 6.01b |
| B: -0.71 (Retained Earnings -4.26b / Total Assets 6.01b) |
| C: 0.01 (EBIT TTM 65.4m / Avg Total Assets 5.98b) |
| D: -0.71 (Book Value of Equity -4.26b / Total Liabilities 6.02b) |
| Altman-Z'' Score: -3.09 = D |
Beneish M -2.86
| DSRI: 1.21 (Receivables 67.6m/53.0m, Revenue 3.12b/2.95b) |
| GMI: 1.00 (GM 27.20% / 27.21%) |
| AQI: 1.08 (AQ_t 0.02 / AQ_t-1 0.02) |
| SGI: 1.06 (Revenue 3.12b / 2.95b) |
| TATA: -0.09 (NI -306.7m - CFO 228.7m) / TA 6.01b) |
| Beneish M-Score: -2.86 (Cap -4..+1) = A |
What is the price of BKD shares?
Over the past week, the price has changed by +4.46%, over one month by +21.05%, over three months by +48.47% and over the past year by +169.20%.
Is BKD a buy, sell or hold?
- StrongBuy: 2
- Buy: 1
- Hold: 1
- Sell: 1
- StrongSell: 0
What are the forecasts/targets for the BKD price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 13.4 | 2.1% |
| Analysts Target Price | 13.4 | 2.1% |
| ValueRay Target Price | 16.1 | 23% |
BKD Fundamental Data Overview January 24, 2026
P/S = 0.9822
P/B = 18.976
P/EG = -0.75
Revenue TTM = 3.12b USD
EBIT TTM = 65.4m USD
EBITDA TTM = 441.3m USD
Long Term Debt = 4.16b USD (from longTermDebt, last quarter)
Short Term Debt = 186.4m USD (from shortTermDebt, last quarter)
Debt = 5.50b USD (from shortLongTermDebtTotal, last quarter)
Net Debt = 5.24b USD (from netDebt column, last quarter)
Enterprise Value = 8.27b USD (3.03b + Debt 5.50b - CCE 253.4m)
Interest Coverage Ratio = 0.21 (Ebit TTM 65.4m / Interest Expense TTM 306.0m)
EV/FCF = 204.3x (Enterprise Value 8.27b / FCF TTM 40.5m)
FCF Yield = 0.49% (FCF TTM 40.5m / Enterprise Value 8.27b)
FCF Margin = 1.30% (FCF TTM 40.5m / Revenue TTM 3.12b)
Net Margin = -9.84% (Net Income TTM -306.7m / Revenue TTM 3.12b)
Gross Margin = 27.20% ((Revenue TTM 3.12b - Cost of Revenue TTM 2.27b) / Revenue TTM)
Gross Margin QoQ = 27.36% (prev 26.56%)
Tobins Q-Ratio = 1.38 (Enterprise Value 8.27b / Total Assets 6.01b)
Interest Expense / Debt = 2.18% (Interest Expense 119.7m / Debt 5.50b)
Taxrate = 21.0% (US default 21%)
NOPAT = 51.6m (EBIT 65.4m * (1 - 21.00%))
Current Ratio = 0.84 (Total Current Assets 536.9m / Total Current Liabilities 637.8m)
Debt / Equity = -816.7 (out of range, set to none) (Debt 5.50b / totalStockholderEquity, last quarter -6.73m)
Debt / EBITDA = 11.88 (Net Debt 5.24b / EBITDA 441.3m)
Debt / FCF = 129.5 (Net Debt 5.24b / FCF TTM 40.5m)
Total Stockholder Equity = 114.5m (last 4 quarters mean from totalStockholderEquity)
RoA = -5.13% (Net Income -306.7m / Total Assets 6.01b)
RoE = -267.9% (Net Income TTM -306.7m / Total Stockholder Equity 114.5m)
RoCE = 1.53% (EBIT 65.4m / Capital Employed (Equity 114.5m + L.T.Debt 4.16b))
RoIC = 1.19% (NOPAT 51.6m / Invested Capital 4.35b)
WACC = 4.35% (E(3.03b)/V(8.53b) * Re(9.12%) + D(5.50b)/V(8.53b) * Rd(2.18%) * (1-Tc(0.21)))
Discount Rate = 9.12% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: 100.0 | Cagr: 1.95%
[DCF Debug] Terminal Value 80.82% ; FCFF base≈40.5m ; Y1≈26.6m ; Y5≈12.1m
Fair Price DCF = N/A (negative equity: EV 386.5m - Net Debt 5.24b = -4.86b; debt exceeds intrinsic value)
[DCF Warning] FCF declining rapidly (-40.0%), DCF may be unreliable
EPS Correlation: 40.77 | EPS CAGR: 34.08% | SUE: -0.23 | # QB: 0
Revenue Correlation: 90.64 | Revenue CAGR: 6.75% | SUE: -0.91 | # QB: 0
EPS next Quarter (2026-03-31): EPS=-0.12 | Chg30d=+0.000 | Revisions Net=-1 | Analysts=1
EPS next Year (2026-12-31): EPS=-0.56 | Chg30d=+0.000 | Revisions Net=-1 | Growth EPS=+50.9% | Growth Revenue=-5.2%